Tetraspanin CD 151 is a novel prognostic marker in poor outcome endometrial cancer


Year:

Session type:

Martin Voss3, Naheema Gordon1, Raji Ganesan2, Linmarie Ludeman4, Keith McCarthy4, Robert Gornall3, Wenbin Wei1, Fedor Berditchevski1, Sudha Sundar1
1School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom,2Department of Pathology, Birmingham Womens Hospital, Birmingham, United Kingdom,3Department of Obstetrics and Gynaecology, Cheltenham General Hospital, Cheltenham, United Kingdom,4Department of Pathology, Cheltenham General Hospital, Cheltenham, United Kingdom

Background

CD151 is a small membrane protein that regulates cell migration and facilitates cancer metastasis. High CD151 expression is associated with poor prognosis in breast, pancreatic and colorectal cancer, and in prostate cancer it is a better prognostic factor than histological grading. Type II endometrial cancers account for 10% of all endometrial carcinomas but are responsible for 50% of cancer recurrence. Response rates to chemotherapy in recurrence is poor. Identification of prognostic markers can help guide therapeutic decision making. 

Objective: To evaluate the prognostic significance of Tetraspanin CD151 expression in a cohort of poor prognosis endometrial cancers of diverse histological type along with Oestrogen Receptor ( ER), Progesterone receptor (PR), p53 and Her-2 expression in the same samples.

Method

A tissue microarray was constructed of 156 consecutive patients with type II endometrial cancer and tested for ER, PR, p53, Her-2 and CD151 expression. 131 (84%) datasets were complete for analysis. Clinical data was collated from a prospective regional database at the South West Public Health Observatory.

Results

Expression of CD151 was significantly associated with uterine papillary serous and clear cell carcinoma than with grade 3 endometrioid carcinoma, sarcoma or MMMT (p < .001). In univariate analysis age, stage, histology type and CD 151 were significant for both recurrence free (RFS) and disease specific survival (DSS). In multivariate analyses CD 151 was signifiacnt for both RFS and DSS (p=0.02 and 0.03 respectively) in the triple negative group 88/131 tumours (ER, PR and Her 2 negative). HER-2, p53, ER and PR were not prognostic for survival.

Conclusion

CD151 is a novel marker in type 2 endometrial cancers that can help guide therapeutic decision making. A larger prospective study to validate these findings is needed.